1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid

CAS : 60239-18-1

Ref. 3D-FT58676

Informations sur le produit

• Nom: 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
• Synonymes: TetraxetanDOTA, 1,4,7,10-Tetra(carboxymethyl)-1,4,7,10-tetraazacyclododecane, 1,4,7,10-Tetraazacyclodecane-1,4,7,10-tetraacetic acid, 1,4,7,10-Tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid, 2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetrayl)Tetraacetic Acid, 2-[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid, Dota, NSC 681107, Tetraxetan
• CAS: 60239-18-1

Description

1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is a metal chelator or radioligand that is used for the diagnosis of cancer. DOTA, as other analogous compounds such as NOTA, TETA and DTPA, has a high affinity for gadolinium and binds to integrin receptors on the surface of cancer cells. It can then be detected by nuclear magnetic resonance spectroscopy or computed tomography. This agent is also used in conjunction with other drugs to treat certain cancers. The most common use of DOTA is as a component of chemotherapy drugs such as docetaxel and cisplatin. DOTA has been shown to be biocompatible with human serum and metabolic response studies have been conducted in animals without any serious side effects. DOTA has shown to be an effective anti-cancer drug for solid tumors in animals and humans with minimal toxicity due to its coordination geometry.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 404.42 g/mol
• Formule: C₁₆H₂₈N₄O₈
• Degré de pureté: Min. 95%
• Couleur/Forme: White Powder
• InChI: InChI=1S/C16H28N4O8/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28)
• Code InChI: InChIKey=WDLRUFUQRNWCPK-UHFFFAOYSA-N
• SMILES: O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1